Glucose-6-phosphate dehydrogenase (G6PD) deficiency

181,676views

Glucose-6-phosphate dehydrogenase (G6PD) deficiency

Watch later

Watch later

Cortisol
Hypercalcemia
Hypocalcemia
Hypoglycemics: Insulin secretagogues
Miscellaneous hypoglycemics
Skeletal muscle histology
Bone remodeling and repair
Fibrous, cartilage, and synovial joints
Cartilage structure and growth
Skeletal system anatomy and physiology
Neuromuscular junction and motor unit
Muscle spindles and golgi tendon organs
Sciatica
Rheumatoid arthritis
Psoriatic arthritis
Reactive arthritis
Ankylosing spondylitis
Dermatomyositis
Polymyalgia rheumatica
Fibromyalgia
Muscular dystrophy
Limited systemic sclerosis (CREST syndrome)
Systemic lupus erythematosus
Antiphospholipid syndrome
Scleroderma
Seronegative and septic arthritis: Pathology review
Systemic lupus erythematosus (SLE): Pathology review
Rheumatoid arthritis and osteoarthritis: Pathology review
Scleroderma: Pathology review
Myalgias and myositis: Pathology review
Glucocorticoids
Non-biologic disease modifying anti-rheumatic drugs (DMARDs)
Osteoporosis medications
Papulosquamous and inflammatory skin disorders: Pathology review
Blood groups and transfusions
Platelet plug formation (primary hemostasis)
Coagulation (secondary hemostasis)
Clot retraction and fibrinolysis
Autoimmune hemolytic anemia
Sickle cell disease (NORD)
Glucose-6-phosphate dehydrogenase (G6PD) deficiency
Hemophilia
Hemolytic-uremic syndrome
Thrombotic thrombocytopenic purpura
Heparin-induced thrombocytopenia
Von Willebrand disease
Disseminated intravascular coagulation
Factor V Leiden
Hodgkin lymphoma
Non-Hodgkin lymphoma
Chronic leukemia
Acute leukemia
Myelodysplastic syndromes
Myelofibrosis (NORD)
Polycythemia vera (NORD)
Essential thrombocythemia (NORD)
Coagulation disorders: Pathology review
Mixed platelet and coagulation disorders: Pathology review
Plasma cell disorders: Pathology review
Platelet disorders: Pathology review
Thrombosis syndromes (hypercoagulability): Pathology review
Leukemias: Pathology review
Myeloproliferative disorders: Pathology review
Anticoagulants: Heparin
Antiplatelet medications
Thrombolytics
Anatomy clinical correlates: Cerebellum and brainstem
Basal ganglia: Direct and indirect pathway of movement
Guillain-Barre syndrome
Charcot-Marie-Tooth disease
Migraine medications

Transcript

Watch video only

Glucose-6-phosphate dehydrogenase deficiency, or G6PD deficiency, is a genetic disorder characterized by decreased levels of glucose-6-phosphate dehydrogenase, which leads to the destruction of red blood cells.

Normally, as a part of the metabolic process, our body produces free radicals like hydrogen peroxide, or H2O2.

Free radicals can damage the cells in many ways including destroying the DNA, proteins, and the cell membrane.

Now, we have a molecule in our body called glutathione which acts as an antioxidant and goes around and neutralizes these free radicals.

In order to function, these molecules need to be in the reduced state where they can donate an electron to the H2O2 and convert them into harmless water and oxygen.

However this causes the glutathione to become oxidized, so before it can get back to work, an enzyme called glutathione reductase will use an NADPH as an electron donor and and reduce the oxidized glutathione back into its working state.

After giving up its electron, the NADPH will become NADP+.

So to replenish the supply of NADPH, we have the glucose-6-phosphate dehydrogenase enzyme, or G6PD, which reduces NADP+ back to NADPH by oxidizing a glucose-6-phosphate.

Glucose-6-phosphate is a metabolite of glucose so we usually have a ready supply of this molecule as long as we are not starving.

Now G6PD deficiency is caused by mutations on the G6PD gene which is found on the X chromosome and thus it’s an X-linked recessive genetic condition and it almost exclusively manifests as a disease in men, since they have one X and one Y chromosome, so if the one and only chromosome has the mutation, then they have the disorder.

Women on the other hand have two X chromosomes, so those with an X chromosome that has the mutation, still have another X chromosome with a normal copy of the gene and thus females are usually carriers and only transmit the disease to their sons.

The G6PD mutations cause defective G6PD enzymes to be produced and these have a shorter half-life, meaning they don’t last as long as the normal enzymes.

There are two common types of G6PD deficiency: a Mediterranean and an African variant.

The Mediterranean variant is characterized by a more markedly reduced half-life of G6PD.

Now, sometimes this can actually be an advantage since it provides protection against falciparum malaria.

G6PD deficiency makes the parasite-infected erythrocyte more susceptible to dying from oxidants, which will also kill the malaria parasites.

So despite the obvious downside to having any of these diseases, they do offer an upside when it comes to warding off a malaria infection.

In fact, because malaria has historically circulated in Africa, the genes underlying these diseases are thought to have conferred a natural selection advantage and therefore became more common in the genetic pool.

Okay, so low levels of G6PD causes low levels of NADPH, leading to low levels of reduced glutathione.

Now G6PD is the only way for red blood cells to get NADPH so they are especially susceptible to damage caused by free radicals.

When these build up, it causes the cell membrane to become unstable, causing their lysis, or hemolysis.

Free radicals can also directly damage hemoglobin molecules which are the oxygen carrying protein in red blood cells.

These damaged proteins precipitates inside the cells and are called Heinz bodies.

The spleen macrophages, that are responsible for eating up old or abnormal red blood cells, notice these Heinz bodies and try to remove them by taking a bite out of the cells, leaving these red blood cells partially devoured, so we call them bite cells.

Now, the good news is that only older red blood cells are at risk for lysis and the hemolytic episode is self-limited as hemolysis stops when only younger red blood cells remain.

Now, when a red blood cell dies, its hemoglobin breaks up into globin and heme.

Heme is converted into bilirubin which is then taken up by the liver cells and eventually secreted out with bile.

Sources

  1. "Harrison's Principles of Internal Medicine, Twentieth Edition (Vol.1 & Vol.2)" McGraw-Hill Education / Medical (2018)
  2. "CURRENT Medical Diagnosis and Treatment 2020" McGraw-Hill Education / Medical (2019)
  3. "Yen & Jaffe's Reproductive Endocrinology" Saunders W.B. (2018)
  4. "Bates' Guide to Physical Examination and History Taking" LWW (2016)
  5. "Robbins Basic Pathology" Elsevier (2017)
  6. "Glucose-6-phosphate dehydrogenase deficiency" Best Practice & Research Clinical Haematology (2000)
  7. "Laboratory diagnosis of G6PD deficiency. A British Society for Haematology Guideline" British Journal of Haematology (2020)
  8. "Laboratory diagnosis of G6PD deficiency. A British Society for Haematology Guideline" British Journal of Haematology (2020)